Lonidamine in Primary Malignant Brain Tumors

Publisher Website
Google Scholar
Abstract
As part of a multicenter study on Lonidamine, this drug was studied in 16 patients with malignant gliomas. General and neurological examination, electroencephalography, electroneuromyography, and CT scan were repeated at regular intervals. The most common side effects were myalgia, nausea, and vomiting which usually subsided during treatment except in 4 patients. There was an indication of therapeutic activity in 4 out of 16 patients treated with Lonidamine.

This publication has 0 references indexed in Scilit: